# CASE REPORT

# Paraspinal abscess secondary to tuberculous spondylitis diagnosed by Xpert MTB/RIF assay in rural Tanzania

Jerry Joseph Hella,<sup>1</sup> Hellen Charles Hiza,<sup>1</sup> Elirehema Mfinanga,<sup>1</sup> Klaus Reither<sup>1,2</sup>

### SUMMARY

<sup>1</sup>Ifakara Health Institute, Bagamoyo, United Republic of Tanzania <sup>2</sup>Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland

**Correspondence to** Dr Klaus Reither, Klaus.Reither@unibas.ch A 31-year-old HIV-negative man presented to our clinic with a 6-month history of back pain and a swelling at the back. Radiological studies revealed lumbar vertebral destruction. Ultrasound of the mass showed a septated cystic mass with turbid fluid. Diagnostic aspiration revealed thick pus and smear microscopy detected acid-fast bacilli. Xpert MTB/RIF assay detected *Mycobacterium tuberculosis* with no rifampicin resistance.

## BACKGROUND

Tuberculous spondylitis (Pott's disease) is the most common manifestation of musculoskeletal tuberculosis (TB). At rural health facilities in high-burden countries, the diagnosis of spinal TB is usually based on clinical and radiological findings. Novel automated nucleic acid amplification tests such as Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) can help to confirm the diagnosis of tuberculous spondylitis without further delay and detect mutations associated with rifampicin resistance. Direct detection of *Mycobacterium tuberculosis* by Xpert MTB/RIF assay in a paraspinal abscess of a patient with tuberculous spondylitis has, to our knowledge, not yet been reported from rural Sub-Saharan Africa.

## **CASE PRESENTATION**

A 31-year-old man reported a 6-month history of back pain and a swelling in the thoracolumbar region. Other symptoms included fever, night sweat, loss of weight and generalised body weakness. No respiratory symptoms were reported. He had no history of prior TB treatment. Upon examination, we saw an anguished patient in poor general condition. He was tachypnoeic with a respiratory rate of 28 breaths/min, while other vital signs were within normal limits. His body mass index was 17.2 kg/m<sup>2</sup>. He had soft, matted, non-tender bilateral axillary and inguinal lymphadenopathies, the largest measuring about 1 cm in diameter. He presented with a gibbus deformity and an obvious fluctuant swelling at the back from the lower thoracic region to the mid-lumbar region measuring 20 cm×11 cm. The swelling was tender and non-pulsatile. Further systemic examination was unremarkable.

To cite: Hella JJ, Hiza HC, Mfinanga E, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2013-009156

# INVESTIGATIONS

The patient tested negative for HIV by both rapid tests SD Bioline HIV 1/2 3.0 (Standard Diagnostics Inc) and Determine HIV-1/2 (Alere Medical Co, Ltd). The patient could not produce any sputum sample. x-Rays of the spinal column showed a soft tissue mass at the back, kyphosis of the lumbar spine with destruction of the inferior end plate of L2 vertebra, wedge deformity of lumbar vertebra L3, complete destruction of intervertebral disc between L2 and L3, and fracture of the anterior surface of the body of L4 vertebra (figures 1 and 2). Chest x-rays revealed small alveolar type of infiltrates at the right upper lobe suggestive of pulmonary TB (figure 3).

Ultrasound of the thoracolumbar swelling showed a septated cystic mass with turbid fluid without visible connection to the spinal cord. The smear microscopy of a fine-needle aspirate taken from the cystic mass revealed acid-fast bacilli while culturing in liquid media was contaminated. Xpert MTB/RIF assay detected *M tuberculosis* complex and no rifampicin resistance strain. Thanks to an easy procedure and the use of Xpert MTB/RIF assay, we could establish the diagnosis of tuberculous spondylitis (Pott's disease) with secondary paraspinal abscess and suspected pulmonary TB.



**Figure 1** A lateral chest x-ray showing a soft tissue mass at the back and kyphosis of the lumbar spine.



**Figure 2** Lateral lumbar spine x-ray showing destruction of the inferior end plate of L2 vertebra, wedge deformity of lumbar vertebra L3, complete destruction of intervertebral disc between L2 and L3 and fracture of the anterior surface of the body of L4 vertebra.



**Figure 3** Posterior–anterior chest x-ray showing small alveolar type of infiltrates in the right upper lobe.

#### OUTCOME AND FOLLOW-UP

We initiated the admission process for the patient to start standard antituberculosis treatment (rifampicin, isoniazid, pyrazinamide and ethambutol) at Bagamoyo District Hospital, Tanzania. The patient, however, refused admission despite counselling. Instead, he was seeking help from a traditional healer without relief from the ailment. Four weeks later, he was seen at the hospital again in even poorer condition. This time he was admitted but passed away after 5 days of TB treatment in the ward.

# DISCUSSION

Extrapulmonary tuberculosis (EPTB) accounts for 15-20% of TB cases.<sup>1 2</sup> Nearly 1–2% of these cases have skeletal system involvement.<sup>3</sup> Tuberculous spondylitis is the most common form of musculoskeletal tuberculosis.<sup>4</sup> Diagnosis of TB should be confirmed by demonstration of tubercle bacilli in a particular lesion. Our report demonstrates that M tuberculosis from a paraspinal abscess in a patient with tuberculous spondylitis can be detected by smear microscopy and confirmed by Xpert MTB/RIF in a rural setting in a timely manner. Fatal outcome of our patient also highlights the need for a rapid diagnosis and treatment in a patient with TB. The Xpert MTB/RIF assay offers a potential solution for improving TB diagnosis especially in peripheral laboratories and clinics.<sup>5</sup> <sup>6</sup> The test has been endorsed by WHO on 8 December 2010 as it is not prone to cross contamination and requires only basic biosafety laboratory.<sup>5–8</sup> Diagnosis can be made in less than 2 h, with knowledge of sensitivity to rifampicin which has treatment implications if found resistant.<sup>6 9</sup> In regards to EPTB, studies have found the sensitivity of Xpert MTB/RIF to be between 80.4% and 81.3% whereas specificity was between 86.1% and 99.8%.1 10-12

The cornerstone to fighting TB is early diagnosis and proper treatment.<sup>9</sup> <sup>13</sup> When it comes to EPTB, this can be a challenge to rural settings due to lack of rapid and accurate diagnostic tools.<sup>14–16</sup> But even though fast and reliable diagnostics are on hand—as in the presented case—lack of awareness and knowledge about the illness and treatment options often pose a larger challenge. Many more lives could be saved in the fight against TB, if members of rural communities trusted modern biomedical medicine more than traditional healers and other non-specialised individuals.

# Learning points

- Xpert MTB/RIF assay offers a potential solution for improving diagnosis of extrapulmonary TB in rural settings.
- Early management of extrapulmonary TB is vital for ensuring survival.
- Extrapulmonary TB can be fatal even to a HIV-negative individual.
- ► Health education seems critical to create understanding for biomedical management of TB in rural settings.

**Contributors** EM and JJH were responsible for the patient care. HCH did the laboratory testing. KR did the X-ray interpretation and is overall in charge of the TB work at the site. HCH developed the first draft and all authors contributed to the finalization of the report.

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

# Novel diagnostic procedure

# REFERENCES

- Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012;40:442–7.
- 2 Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res 2004;120:316–53.
- 3 Agrawal V, Patgaonkar PR, Nagariya SP. Tuberculosis of spine. J Craniovertebral Junction Spine 2010;1:74–85.
- 4 Tuli SM. *Tuberculosis of the skeletal system: bones, joints, spine and bursal sheaths.* 3rd edition. New Delhi, India: Jaypee Brothers Publishers, 2004.
- 5 Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48:229–37.
- 6 Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *Lancet* 2011;377:1495–505.
- 7 Hillemann D, Rüsch-Gerdes S, Boehme C, et al. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 2011;49:1202–5.

- 8 Steingart KR, Sohn H, Schiller I, *et al.* Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (review). *Cochrane Database Syst Rev* 2013;1:CD009593.
- 9 Cox H, Kebede Y, Allamuratova S, *et al*. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. *PLoS Med* 2006;3:8.
- 10 Lange C, Sester M, Sotgiu G, et al. Interferon-gamma release assays for diagnosis of active pleural tuberculosis: a developing world perspective. Eur Respir J 2011;38:746.
- 11 Vadwai V, Boehme C, Nabeta P, et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011;49:2540–5.
- 12 Chang K, Lu W, Wang J, *et al*. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. *J Infect* 2012;64:580–8.
- 13 Chakravorty S, Boehme C, Lee J. Tuberculosis diagnostics in the new millennium: role in TB identification and control. *Tuberc Res Treat* 2012;2012:1–2.
- 14 Small PM, Pai M. Tuberculosis diagnosis—time for a game change. *N Engl J Med* 2010;363:1070–1.
- 15 Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. *Am Fam Physician* 2005;72:1761–8.
- 16 Parsons LM, Somoskövi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clin Microbiol Rev* 2011;24:314–50.

Copyright 2013 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- ► Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- ► Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow